Join us for an engaging webinar focused on the intriguing interplay between inflammatory bowel diseases (IBD) and neutrophil activity, with a special emphasis on the insights provided by the unique CPa9-HNE serum calprotectin.
Our experts will unravel the biological processes of mucosal damage and healing in inflammatory bowel disease (IBD), and how it relates to neutrophil activity and the extracellular matrix (ECM). Specifically, we will delve into the role of mucosal damage, intestinal fibrosis, and fibro-inflammation, and how they impact ECM remodeling and integrity.
In this edition of the ECM Pharmacology Symposium Series, we will address the mechanisms of neutrophil activity in chronic diseases, in particular on fibro-inflammation in inflammatory bowel diseases, focusing in particular on fibro-inflammation and mucosal damage.
We will also present the latest methods for quantifying fibro-inflammation in IBD, such as the novel serum calprotectin biomarker CPa9-HNE, and discuss the implications of these findings for patients. In addition, we will look at current and future treatment options for IBD and the potential impact of these advances on patient outcomes.
This webinar is an excellent opportunity for researchers, clinicians, and healthcare professionals to gain valuable insight into the latest developments in IBD research and treatment, and to gain a deeper understanding of the intricate interplay of neutrophil activity, mucosal damage and fibro-inflammation in IBD.
Speaker line-up and agenda:
0:00 Intro
4:38 Dr. Anne Bay-Jensen: The role of neutrophil activity in tissue destruction
15:35 Dr. Florian Rieder: Mucosal damage and intestinal fibrosis in IBD
50:30 Dr. Joachim Høg Mortensen: Fibro-inflammation in IBD: new frontier and how to quantify it
1:17:00 General discussion and Q&A